New therapies for immune thrombocytopenic purpura
Purpura, Thrombocytopenic, Idiopathic
Rho(D) Immune Globulin
Clinical investigation of novel therapies in immune thrombocytopenic purpura is undergoing a revolution that has the potential to change the standard of care. While older therapies are experiencing a rebirth by being given a new spin, newer agents such as thrombopoietins are showing significant promise.